A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer

Inclusion Criteria: * Voluntarily participated in this study and signed the informed consent form, with good compliance and cooperation during the follow-up; * Male or female aged 18 years or above; * Patients diagnosed with oligometastatic esophageal squamous cell carcinoma through imaging. Oligometastatic esophageal cancer is defined as having no more than 5 metastatic lesions other than the primary tumor at the initial diagnosis or during treatment, and the metastatic lesions involve no more than 2 distant organs, and the disease duration is more than 3 months; * At least one measurable lesion according to the RECIST 1.1 standard; * Expected lifespan of at least 3 months; * ECOG (Eastern Cooperative Oncology Group) score: 0-1 point; * Adequate organ and bone marrow functions; * For fertile women, appropriate contraceptive measures must be taken from the screening to 3 months after stopping the study treatment, and must be non-lactating subjects. Before starting the medication, the pregnancy test should be negative. For men, they must agree to use appropriate methods of contraception during the trial and for 8 weeks after the last administration of the trial drug or have undergone surgical sterilization. Exclusion Criteria: * Have received PD-1/PD-L1/CTLA-4 antibody or anti-angiogenic drugs (such as sunitinib, sorafenib, regorafenib, bevacizumab, imatinib, apatinib, etc.) in the past; * Have participated in other drug clinical trials within the past 4 weeks or received s…